FDA Brief

Warning letters Drugs

FDA warning letter to

Dyno Manufacturing, Inc.

High riskIssued Apr 9, 2025Posted Apr 29, 2025Center for Drug Evaluation and Research (CDER)

Dyno Manufacturing’s OTC hand sanitizer and antibacterial soap drugs lacked raw-material identity testing and other required manufacturing controls.

What happened

FDA inspected Dyno Manufacturing’s drug manufacturing facility in Madison, IL, from October 28 to November 1, 2024. FDA found that the firm did not adequately test incoming raw materials, including glycerin for diethylene glycol (DEG) or ethylene glycol (EG) and ethanol for methanol, and lacked stability testing, process validation, equipment qualification, cleaning validation, and adequate quality-unit oversight. FDA reviewed the firm’s November 21, 2024 response to the inspection observations (Form FDA 483) and found it inadequate in several areas.

What FDA found

  1. The firm did not test each incoming component lot for identity and did not establish the reliability of supplier certificates of analysis.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  2. The firm used glycerin and other high-risk components without United States Pharmacopeia (USP) identity testing to detect diethylene glycol (DEG) and ethylene glycol (EG).

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  3. The firm used ethanol without adequate testing for methanol and relied on supplier certificates of analysis that did not include methanol results.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  4. The firm did not have stability testing to support the expiration dates assigned to its OTC drug products.

    21 CFR 211.137(a)
  5. The firm did not validate its manufacturing processes or qualify its equipment and cleaning processes.

    21 CFR 211.100(a)
  6. The quality control unit did not ensure annual product reviews, adequate written procedures, and computer-system controls.

    21 CFR 211.22; 21 CFR 211.180(e); 21 CFR 211.22(d); 21 CFR 211.68(b)

What FDA wants

FDA tells the firm to correct the violations promptly and respond in writing within 15 working days with corrective actions and supporting data; it also requires DEG/EG test results no later than 30 calendar days from the letter date.

Who should pay attention

  • companies that buy OTC hand sanitizer or antibacterial soap from Dyno
  • contract manufacturers and brands relying on supplier certificates of analysis
  • quality teams handling glycerin, ethanol, or other high-risk raw materials

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. ABS Corporation

    ABS Corporation released out-of-specification veterinary drugs and used inadequately tested raw materials, FDA says.

    High risk
  2. King Farm

    King Farm's horse feed held fumonisin up to 36.1 ppm; FDA ties it to at least 30 horse deaths.

    High risk
  3. Daewoo Pharmaceutical Co., Ltd.

    FDA warns Daewoo Pharmaceutical over CGMP (manufacturing quality rules) failures at Busan plant; company suspended production.

    High risk
  4. Horizon Tool Inc.

    FDA warns Horizon Tool over manufacturing-rule violations for AllShield E2 Sanitizing Hand Soap.

    High risk